Calliditas Therapeutics AB (publ) (NASDAQ Stockholm: CALTX), a specialty pharmaceutical company based in Stockholm, Sweden, announced yesterday that it has named Dr Frank Bringstrup as its new vice president regulatory affairs, effective 1 February 2019.
As a member of the company's management team, Bringstrup will have a leading role in the regulatory discussions and approval process for the company's pivotal clinical phase three study, NEFIGARD, in patients with IgA nephropathy (IgAN).
Dr Bringstrup has more than 17 years experience in the pharmaceutical industry in regulatory affairs and health authority interactions. He worked in various positions at Novo Nordisk A/S, most recently as its senior global regulatory lead. During his time at Novo Nordisk, he led the strategic regulatory input for the orphan drug NovoEight all the way from phase one to phase three with five parallel MAAs and NDAs and five major approvals gained in a 15-month period. He has a wealth of experience of Regulatory Affairs in the US, EU, Japanese and international markets, and was, among other projects, responsible for overseeing the lifecycle development for new indications for the orphan drug NovoSeven, a recombinant human coagulation Factor VIIa (rFVIIa), intended for promoting haemostasis by activating the extrinsic pathway of the coagulation cascade.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer